EAST Search History

Ref #	Hits	Search Query	DBs	Default Operator	Plurals	Time Stamp
L1	247	536/27.1.ccls.	US-PGPUB; USPAT	OR	ON	2007/04/01 17:18
L2	149	536/27.13.ccls.	US-PGPUB; USPAT	OR	ON	2007/04/01 17:18
L3	123	536/27.2.ccls.	US-PGPUB; USPAT	OR	ON	2007/04/01 17:18
L4	148	536/27.21.ccls.	US-PGPUB; USPAT	OR	ON	2007/04/01 17:19
L5	743	514/45.ccls.	US-PGPUB; USPAT	OR	ON	2007/04/01 17:19
L6	851	514/46.ccls.	US-PGPUB; USPAT	OR	ON	2007/04/01 17:19
L7	1725	1 2 3 4 5 6	US-PGPUB; USPAT	OR	ON	2007/04/01 17:19

C:\Program Files\Stnexp\Queries\10540993b.str





chain nodes :
15 16 23 24 25 26 27 28 29 30 31 32 33 34
ring nodes :
1 2 3 4 5 6 7 8 9 10 11 12 13 14 17 18 19 20 21 22
chain bonds :
4-15 8-33 9-14 10-23 10-31 11-24 11-30 12-25 14-32 15-16 16-22 23-29 24-28 25-26 26-27
ring bonds :
1-2 1-6 2-3 3-4 4-5 5-6 5-7 6-9 7-8 8-9 10-11 10-14 11-12 12-13 13-14 17-18 17-22 18-19 19-20 20-21 21-22
exact/norm bonds :
1-2 1-6 2-3 3-4 4-5 4-15 5-6 5-7 6-9 7-8 8-9 9-14 10-11 10-14 10-23 11-12 11-24 12-13 13-14
exact bonds :
8-33 10-31 11-30 12-25 14-32 15-16 16-22 23-29 24-28 25-26 26-27
normalized bonds :
17-18 17-22 18-19 19-20 20-21 21-22

Match level :
1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:Atom 11:Atom 12:Atom 13:Atom 14:Atom 15:CLASS 16:CLASS 17:Atom 18:Atom 19:Atom 20:Atom 21:Atom 22:Atom 23:CLASS 24:CLASS 25:CLASS 26:CLASS 27:CLASS 28:CLASS 29:CLASS 30:CLASS 31:CLASS 32:CLASS 33:CLASS 34:CLASS 35:Atom

```
RE.CNT  21    THERE ARE 21 CITED REFERENCES AVAILABLE FOR THIS RECORD
              ALL CITATIONS AVAILABLE IN THE RE FORMAT


=> d his

     (FILE 'HOME' ENTERED AT 13:42:38 ON 01 APR 2007)

     FILE 'REGISTRY' ENTERED AT 13:43:00 ON 01 APR 2007
L1              STRUCTURE UPLOADED
L2            5 S L1 SSS SAM
L3           72 S L1 SSS FULL

     FILE 'CAPLUS' ENTERED AT 13:43:48 ON 01 APR 2007
L4           12 S L3

     FILE 'REGISTRY' ENTERED AT 15:45:12 ON 01 APR 2007
L5              STRUCTURE UPLOADED
L6           50 S L5 SSS SAM
L7              STRUCTURE UPLOADED
L8           50 S L7 SSS SAM
L9              STRUCTURE UPLOADED
L10          50 S L9 SSS SAM
L11        2260 S L9 SSS FULL

     FILE 'CAPLUS' ENTERED AT 15:52:44 ON 01 APR 2007
L12         191 S L11
```

10/540,993

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:SSSPTA1600TXM

PASSWORD:
* * * * * * RECONNECTED TO STN INTERNATIONAL * * * * * *
SESSION RESUMED IN FILE 'CAPLUS' AT 15:45:00 ON 01 APR 2007
FILE 'CAPLUS' ENTERED AT 15:45:00 ON 01 APR 2007
COPYRIGHT (C) 2007 AMERICAN CHEMICAL SOCIETY (ACS)

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	65.59	237.90

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	-9.36	-9.36

=> FILE REG

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	65.59	237.90

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	-9.36	-9.36

FILE 'REGISTRY' ENTERED AT 15:45:12 ON 01 APR 2007
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2007 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file
provided by InfoChem.

STRUCTURE FILE UPDATES: 30 MAR 2007 HIGHEST RN 928818-37-5
DICTIONARY FILE UPDATES: 30 MAR 2007 HIGHEST RN 928818-37-5

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH December 2, 2006

Please note that search-term pricing does apply when
conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and
predicted properties as well as tags indicating availability of
experimental property data in the original document. For information
on property searching in REGISTRY, refer to:

http://www.cas.org/ONLINE/UG/regprops.html

=>
Uploading C:\Program Files\Stnexp\Queries\10540993.str

L5 STRUCTURE UPLOADED

=> D L5
L5 HAS NO ANSWERS
L5 STR

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

Structure attributes must be viewed using STN Express query preparation.

=> S L5 SSS SAM
SAMPLE SEARCH INITIATED 15:45:48 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED - 431 TO ITERATE

McIntosh

100.0% PROCESSED 431 ITERATIONS 50 ANSWERS
INCOMPLETE SEARCH (SYSTEM LIMIT EXCEEDED)
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **COMPLETE**
BATCH **COMPLETE**
PROJECTED ITERATIONS: 7375 TO 9865
PROJECTED ANSWERS: 1847 TO 3193

L6 50 SEA SSS SAM L5

=> d l6

L6 ANSWER 1 OF 50 REGISTRY COPYRIGHT 2007 ACS on STN
RN 905578-97-4 REGISTRY
ED Entered STN: 31 Aug 2006
CN Adenosine, N-(phenylmethyl)-, 5'-sulfamate (9CI) (CA INDEX NAME)
FS STEREOSEARCH
MF C17 H20 N6 O6 S
SR CA
LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

=>
Uploading C:\Program Files\Stnexp\Queries\10540993a.str

L7 STRUCTURE UPLOADED

=> s l7 sss sam
SAMPLE SEARCH INITIATED 15:48:53 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED - 431 TO ITERATE

100.0% PROCESSED 431 ITERATIONS 50 ANSWERS
INCOMPLETE SEARCH (SYSTEM LIMIT EXCEEDED)
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **COMPLETE**
BATCH **COMPLETE**
PROJECTED ITERATIONS: 7375 TO 9865
PROJECTED ANSWERS: 1709 TO 3011

L8 50 SEA SSS SAM L7

=> d l1
L1 HAS NO ANSWERS
L1 STR

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

Structure attributes must be viewed using STN Express query preparation.

=> d

McIntosh

L8 ANSWER 1 OF 50 REGISTRY COPYRIGHT 2007 ACS on STN
RN 765299-62-5 REGISTRY
ED Entered STN: 19 Oct 2004
CN Adenosine, N-[(3-iodophenyl)methyl]-2-[4-(2-pyridinyl)-1H-pyrazol-1-yl]-
(9CI) (CA INDEX NAME)
FS STEREOSEARCH
MF C25 H23 I N8 O4
SR CA
LC STN Files: CA, CAPLUS, CASREACT

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

=>
Uploading C:\Program Files\Stnexp\Queries\10540993b.str

L9 STRUCTURE UPLOADED

=> s l9 sss sam
SAMPLE SEARCH INITIATED 15:52:10 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED - 431 TO ITERATE

100.0% PROCESSED 431 ITERATIONS 50 ANSWERS
INCOMPLETE SEARCH (SYSTEM LIMIT EXCEEDED)
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **COMPLETE**
BATCH **COMPLETE**
PROJECTED ITERATIONS: 7375 TO 9865
PROJECTED ANSWERS: 1640 TO 2920

L10 50 SEA SSS SAM L9

=> d

L10 ANSWER 1 OF 50 REGISTRY COPYRIGHT 2007 ACS on STN
RN 765299-62-5 REGISTRY
ED Entered STN: 19 Oct 2004
CN Adenosine, N-[(3-iodophenyl)methyl]-2-[4-(2-pyridinyl)-1H-pyrazol-1-yl]-
(9CI) (CA INDEX NAME)
FS STEREOSEARCH
MF C25 H23 I N8 O4
SR CA

McIntosh

10/540,993

LC STN Files: CA, CAPLUS, CASREACT

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

=> s l9 sss full
FULL SEARCH INITIATED 15:52:39 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED - 8204 TO ITERATE

100.0% PROCESSED 8204 ITERATIONS 2260 ANSWERS
SEARCH TIME: 00.00.01

L11 2260 SEA SSS FUL L9

=> file caplus

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	183.35	421.25
DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	0.00	-9.36

FILE 'CAPLUS' ENTERED AT 15:52:44 ON 01 APR 2007
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

FILE COVERS 1907 - 1 Apr 2007 VOL 146 ISS 15
FILE LAST UPDATED: 30 Mar 2007 (20070330/ED)

Effective October 17, 2005, revised CAS Information Use Policies apply.
They are available for your review at:

McIntosh

http://www.cas.org/infopolicy.html

```
=> s l11
L12        191 L11

=> d bib 10 l12

L12  ANSWER 10 OF 191  CAPLUS  COPYRIGHT 2007 ACS on STN
AN   2005:1200866  CAPLUS
DN   143:452893
TI   Use of N-desmethylclozapine to treat human neuropsychiatric disease
IN   Weiner, David M.; Brann, Mark R.
PA   USA
SO   U.S. Pat. Appl. Publ., 38 pp., Cont.-in-part of U.S. Ser. No. 913,117.
     CODEN: USXXCO
DT   Patent
LA   English
FAN.CNT 4
     PATENT NO.          KIND   DATE        APPLICATION NO.        DATE
     --------------      ----   --------    -------------------    --------
PI   US 2005250767        A1    20051110    US 2005-98892          20050404
     US 2004224942        A1    20041111    US 2004-761787         20040121
     US 2005085463        A1    20050421    US 2004-913117         20040805
     WO 2006017614        A1    20060216    WO 2005-US27645        20050804
         W:  AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH,
             CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD,
             GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ,
             LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA,
             NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK,
             SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU,
             ZA, ZM, ZW
         RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE,
             IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ,
             CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH,
             GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY,
             KG, KZ, MD, RU, TJ, TM
     US 2006194831        A1    20060831    US 2006-416565         20060503
     US 2006199807        A1    20060907    US 2006-417069         20060503
PRAI US 2003-442690P      P     20030123
     US 2004-761787       A2    20040121
     US 2004-913117       A2    20040805
     US 2004-617553P      P     20041008
     US 2005-98892        A     20050404


=> d bib 20 l12

L12  ANSWER 20 OF 191  CAPLUS  COPYRIGHT 2007 ACS on STN
AN   2004:634314  CAPLUS
DN   141:296236
TI   2-Pyrazolyl-N6-Substituted Adenosine Derivatives as High Affinity and
     Selective Adenosine A3 Receptor Agonists
AU   Elzein, Elfatih; Palle, Venkata; Wu, Yuzhi; Maa, Tenning; Zeng, Dewan;
     Zablocki, Jeff
CS   Department of Bioorganic Chemistry and Department of Drug Research and
     Pharmacological Sciences, CV Therapeutics Inc., Palo Alto, CA, 94304, USA
SO   Journal of Medicinal Chemistry (2004), 47(19), 4766-4773
     CODEN: JMCMAR; ISSN: 0022-2623
PB   American Chemical Society
DT   Journal
LA   English
OS   CASREACT 141:296236
RE.CNT  23    THERE ARE 23 CITED REFERENCES AVAILABLE FOR THIS RECORD
              ALL CITATIONS AVAILABLE IN THE RE FORMAT


=> d bib 30 l12

L12  ANSWER 30 OF 191  CAPLUS  COPYRIGHT 2007 ACS on STN
AN   2003:967197  CAPLUS
DN   140:193623
TI   Allosteric enhancers of A1 adenosine receptors increase receptor-G protein
     coupling and counteract guanine nucleotide effects on agonist binding
AU   Figler, Heidi; Olsson, Ray A.; Linden, Joel
```

CS Cardiovascular Research Center, University of Virginia, Charlottesville, VA, USA
SO Molecular Pharmacology (2003), 64(6), 1557-1564
CODEN: MOPMA3; ISSN: 0026-895X
PB American Society for Pharmacology and Experimental Therapeutics
DT Journal
LA English
RE.CNT 30 THERE ARE 30 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> d bib 40 l12

L12 ANSWER 40 OF 191 CAPLUS COPYRIGHT 2007 ACS on STN
AN 2002:356410 CAPLUS
DN 137:185753
TI Solid phase synthesis of C2,N6-disubstituted adenosine analogues
AU Rodenko, Boris; Wanner, Martin J.; Koomen, Gerrit-Jan
CS Laboratory of Organic Chemistry, Institute of Molecular Chemistry, University of Amsterdam, Amsterdam, NL-1018 WS, Neth.
SO Journal of the Chemical Society, Perkin Transactions 1 (2002), (10), 1247-1252
CODEN: JCSPCE; ISSN: 1472-7781
PB Royal Society of Chemistry
DT Journal
LA English
OS CASREACT 137:185753
RE.CNT 30 THERE ARE 30 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> d bib abs hitstr 40-50 l12

L12 ANSWER 40 OF 191 CAPLUS COPYRIGHT 2007 ACS on STN
AN 2002:356410 CAPLUS
DN 137:185753
TI Solid phase synthesis of C2,N6-disubstituted adenosine analogues
AU Rodenko, Boris; Wanner, Martin J.; Koomen, Gerrit-Jan
CS Laboratory of Organic Chemistry, Institute of Molecular Chemistry, University of Amsterdam, Amsterdam, NL-1018 WS, Neth.
SO Journal of the Chemical Society, Perkin Transactions 1 (2002), (10), 1247-1252
CODEN: JCSPCE; ISSN: 1472-7781
PB Royal Society of Chemistry
DT Journal
LA English
OS CASREACT 137:185753
AB A 6-step solid phase sequence towards C2,N6-disubstituted adenosine analogs was developed, which was validated by the construction of a small combinatorial library. Attachment of the 5'-OH of readily available 2',3'-methoxymethylidene protected 6-chloropurine ribonucleoside onto carboxypolystyrene furnished the immobilized 6-chloropurine ribonucleoside. Nitration on the solid phase resulted in the formation of the 2-nitro-6-chloropurine nucleoside, a highly reactive difunctionalized species. Amines were selectively introduced at the 6-position by 6-chloro displacement at room temperature without affecting the 2-nitro group. Subsequent substitution of the 2-nitro group by amines was achieved at 80-90 °C. Removal of the methoxymethylidene group under mildly acidic conditions, followed by cleavage of the nucleosides from the resin, yielded the C2,N6-disubstituted adenosine analogs.
IT 452071-03-3P 452071-04-4P 452071-05-5P
452071-06-6P
RL: CPN (Combinatorial preparation); CMBI (Combinatorial study); PREP (Preparation)
(solid phase synthesis of a small combinatorial library of C2,N6-disubstituted adenosine analogs)
RN 452071-03-3 CAPLUS
CN Adenosine, 2-(cyclopentylamino)-N-[(3-iodophenyl)methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 452071-04-4 CAPLUS
CN Adenosine, 2-[[2-(1H-indol-3-yl)ethyl]amino]-N-[(3-iodophenyl)methyl]-
(9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 452071-05-5 CAPLUS
CN Adenosine, N-[(3-iodophenyl)methyl]-2-[[2-(phenylmethoxy)ethyl]amino]-
(9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 452071-06-6 CAPLUS
CN Adenosine, 2-[[2-(1H-imidazol-4-yl)ethyl]amino]-N-[(3-iodophenyl)methyl]-
(9CI) (CA INDEX NAME)

Absolute stereochemistry.



RE.CNT 30 THERE ARE 30 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L12 ANSWER 41 OF 191 CAPLUS COPYRIGHT 2007 ACS on STN
AN 2002:211819 CAPLUS
DN 137:30541
TI Aromatic cytokinins in micropropagated potato plants
AU Baroja-Fernandez, Edurne; Aguirreolea, Jone; Martinkova, Hana; Hanus, Jan; Strnad, Miroslav
CS Facultades de Ciencias y Farmacia, Departamento de Fisiologia Vegetal, Universidad de Navarra, Pamplona, 31008, Spain
SO Plant Physiology and Biochemistry (Paris, France) (2002), 40(3), 217-224
CODEN: PPBIEX; ISSN: 0981-9428
PB Editions Scientifiques et Medicales Elsevier
DT Journal
LA English
AB Endogenous cytokinins were studied in three micropropagated Solanum tuberosum L. cultivars (Kennebec, Turia and Jaerla) differing in survival after transplanting. Leaf and stem cytokinins were determined both in vitro and 10 d after being transferred to ex vitro conditions by a combination of high-performance liquid chromatog. and ELISA. Nine aromatic and nine isoprenoid type cytokinins were identified. Higher levels of total cytokinins mainly aroms. (92%) were detected in Kennebec, the cultivar showing better in vitro growth and 99% survival. On the contrary, a predominance of isoprenoid cytokinins (up to 57%) was observed after transplanting in Jaerla, the cultivar showing lower viability. Significant survival improvement was obtained in the Jaerla cultivar after addition to the culture medium of the aromatic cytokinin meta-topolin riboside (mTR). We also report here isolation and identification of this cytokinin by several sophisticated techniques including mTR-specific immunoaffinity chromatog., diode-array high-performance liquid chromatog. (HPLC), and gas chromatog.-mass spectrometry of permethylated HPLC fractions. The occurrence of the aromatic cytokinins in potato plants is described for the first time.
IT 50868-58-1, Ortho-topolin riboside
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(aromatic cytokinins in micropropagated potato plants)
RN 50868-58-1 CAPLUS
CN Adenosine, N-[(2-hydroxyphenyl)methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT 110505-76-5, Meta-topolin riboside
RL: BSU (Biological study, unclassified); BUU (Biological use, unclassified); BIOL (Biological study); USES (Uses)
(aromatic cytokinins in micropropagated potato plants in relation to survival and growth)
RN 110505-76-5 CAPLUS
CN Adenosine, N-[(3-hydroxyphenyl)methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RE.CNT 40 THERE ARE 40 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L12 ANSWER 42 OF 191 CAPLUS COPYRIGHT 2007 ACS on STN
AN 2002:184937 CAPLUS
DN 136:226791
TI Remedies for heart failure
IN Kawashima, Kayoko; Katsuragi, Naruto; Sugimura, Keijiro; Furuya, Mayumi; Morishita, Ryuichi
PA Suntory Limited, Japan; Suntory Biomedical Research Limited
SO PCT Int. Appl., 81 pp.
CODEN: PIXXD2
DT Patent
LA Japanese
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2002020055	A1	20020314	WO 2001-JP7787	20010907
	W: AU, CA, CN, HU, IL, JP, KR, US				
	RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR				
	CA 2431711	A1	20020314	CA 2001-2431711	20010907
	AU 2001084483	A5	20020322	AU 2001-84483	20010907
	EP 1319408	A1	20030618	EP 2001-963519	20010907
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI, CY, TR				
	HU 200301729	A2	20030929	HU 2003-1729	20010907

	US 2004029827	A1	20040212	US 2003-383241	20030716
	AU 2006235936	A1	20061130	AU 2006-235936	20061109
PRAI	JP 2000-273644	A	20000908		
	WO 2001-JP7787	W	20010907		

OS MARPAT 136:226791

AB A method of screening a drug capable of inhibiting the expression of an OSF-2 gene or the production or function of the protein, and remedies for heart failure having these effects are provided. By monitoring the expression and variation of the above gene or the production of the protein, a useful method of diagnosing heart failure can be provided. Moreover, a transgenic animal in which the OSF-2 gene is forcedly expressed, and a method of examining changes in the gene expression or the protein production in association with the progress of the pathol. conditions of heart failure or the functions of various genes or proteins by using such a transgenic animal are provided.

IT 23707-33-7
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(antisense nucleotides and adenosine analogs as inhibitors of OSF-2 gene expression for treatment of heart failure)

RN 23707-33-7 CAPLUS

CN Adenosine, N-[(2-methylphenyl)methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RE.CNT 7 THERE ARE 7 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L12 ANSWER 43 OF 191 CAPLUS COPYRIGHT 2007 ACS on STN

AN 2002:171918 CAPLUS

DN 136:217007

TI Preparation of antiviral nucleoside derivatives as inhibitors of subgenomic hepatitis C virus RNA replication

IN Devos, Rene; Dymock, Brian William; Hobbs, Christopher John; Jiang, Wen-rong; Martin, Joseph Armstrong; Merrett, John Herbert; Najera, Isabel; Shimma, Nobuo; Tsukuda, Takuo

PA F. Hoffmann-La Roche Ag, Switz.

SO PCT Int. Appl., 225 pp.
CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2002018404	A2	20020307	WO 2001-EP9633	20010821
WO 2002018404	A9	20031002		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW

RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

	US 2003008841	A1	20030109	US 2001-923620	20010807
	CA 2419399	A1	20020307	CA 2001-2419399	20010821
	AU 2001095497	A5	20020313	AU 2001-95497	20010821
	EP 1315736	A2	20030604	EP 2001-976128	20010821
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
	BR 2001013611	A	20030624	BR 2001-13611	20010821
	JP 2004513083	T	20040430	JP 2002-523918	20010821
	ZA 2003001540	A	20040621	ZA 2003-1540	20030225
	US 2004110718	A1	20040610	US 2003-678804	20031003
PRAI	GB 2000-21285	A	20000830		
	GB 2000-26611	A	20001031		
	US 2001-923620	B1	20010807		
	WO 2001-EP9633	W	20010821		

OS MARPAT 136:217007

GI



I



II

AB Nucleosides I , wherein R1 is hydrogen, hydroxy, alkyl, hydroxyalkyl, alkoxy, halogen, cyano, isocyano or azido; R2 is hydrogen, hydroxy, alkoxy, chlorine, bromine or iodine; R3 is hydrogen; or R2 and R3 together represent =CH2; or R2 and R3 represent fluorine; X is O, S or CH2; B is a substituted purine base, were prepared as inhibitors of subgenomic hepatitis C virus (HCV) RNA replication. Thus, nucleoside II was prepared and tested for the inhibition of HCV RNA replication (EC50 = 0.6 μM).

IT 23707-33-7P 95523-13-0P 402725-47-7P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of antiviral nucleoside derivs. as inhibitors of subgenomic hepatitis C virus RNA replication)

RN 23707-33-7 CAPLUS

CN Adenosine, N-[(2-methylphenyl)methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 95523-13-0 CAPLUS

CN Adenosine, N-[(4-aminophenyl)methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

McIntosh



RN 402725-47-7 CAPLUS
CN Adenosine, N-[(4-chloro-2-methoxyphenyl)methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L12 ANSWER 44 OF 191 CAPLUS COPYRIGHT 2007 ACS on STN
AN 2002:89069 CAPLUS
DN 136:355407
TI Anti-Malarial activity of N6-Substituted adenosine derivatives. Part I
AU Golisade, Abolfasl; Wiesner, Jochen; Herforth, Claudia; Jomaa, Hassan; Link, Andreas
CS Institut fur Pharmazie, Universitat Hamburg, Hamburg, D-20146, Germany
SO Bioorganic & Medicinal Chemistry (2002), 10(3), 769-777
CODEN: BMECEP; ISSN: 0968-0896
PB Elsevier Science Ltd.
DT Journal
LA English
OS CASREACT 136:355407
AB The synthesis and biol. evaluation of novel N6-substituted adenosine derivs. is reported. The first series of compds. was obtained using an established procedure for the nucleophilic substitution of a 1-(6-chloro-purin-9-yl)-β-D-1-deoxy-ribofuranose with various amines. In addition, attachment of two different amino-functionalized spacer arms at the N6-position of adenosine enabled derivatization by an innovative polymer-assisted protocol. Thus, we were able to prepare three series of substituted derivs. that displayed activity vs. the multiresistant Plasmodium falciparum strain Dd2 in cell culture expts.
IT 420116-40-1P 420116-41-2P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
(preparation of and antimalarial structure activity relationship of

N6-Substituted adenosine derivs.)
RN 420116-40-1 CAPLUS
CN Adenosine, N-[(3,5-difluorophenyl)methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 420116-41-2 CAPLUS
CN Adenosine, N-[(2,4-dimethoxyphenyl)methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RE.CNT 15 THERE ARE 15 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L12 ANSWER 45 OF 191 CAPLUS COPYRIGHT 2007 ACS on STN
AN 2001:766039 CAPLUS
DN 136:34878
TI Effect of benzyladenine and hydroxybenzyladenosine on gas exchange of bean and sugar beet leaves
AU Pospisilova, J.; Rulcova, J.; Vomacka, L.
CS Institute of Experimental Botany, Academy of Sciences of the Czech Republic, Prague, CZ-160 00/6, Czech Rep.
SO Biologia Plantarum (2001), 44(4), 523-528
CODEN: BPABAJ; ISSN: 0006-3134
PB Institute of Experimental Botany, Academy of Sciences of the Czech Republic
DT Journal
LA English
AB Using bean seedlings, the effects of benzyladenine (BA) on stomatal conductance (gs), transpiration rate (E), and net photosynthetic rate (PN) were examined in order to find out dose and time responses. In bean seedlings, BA applied to roots in concns. of 1, 5, 10, and 20 μM increased gs and PN of leaves already 1 h after application. E was not markedly affected and water use efficiency (WUE) was increased. However, the effects were mostly transient and after 24 h PN only at 1 and 5 μM

BA was increased, and other parameters were not affected or even decreased. In sugar beet seedlings, the effects of hydroxybenzyladenosine (HBA) in addition to those of BA on the same parameters were determined The both cytokinins were applied in 1, 5, 10, and 20 μM concns. either to roots or sprayed on leaves. However, the effects were inconsistent and the pos. effect was observed only after 24 h on PN in plants with roots immersed in 5 and 10 μM BA, or 10 μM HBA, and on E in plants sprayed with 5 μM BA or 10 μM HBA. Thus, the stimulation of gas exchange by exogenously applied cytokinins is rather exceptional than general.

IT 110505-76-5
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(effect of benzyladenine and hydroxybenzyladenosine on gas exchange of bean and sugar beet leaves)
RN 110505-76-5 CAPLUS
CN Adenosine, N-[(3-hydroxyphenyl)methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RE.CNT 37 THERE ARE 37 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L12 ANSWER 46 OF 191 CAPLUS COPYRIGHT 2007 ACS on STN
AN 2001:757814 CAPLUS
DN 135:298819
TI Meta-substituted acidic 8-phenylxanthine antagonists of A3 human adenosine receptors, and their therapeutic use
IN Linden, Joel M.
PA University of Virginia, USA; University of Virginia Patent Foundation
SO U.S., 16 pp.
CODEN: USXXAM
DT Patent
LA English
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI US 6303619	B1	20011016	US 1998-38991	19980312
PRAI US 1998-38991		19980312		

OS MARPAT 135:298819
AB The invention concerns the use of a xanthine or xanthine derivative having a meta-substituted acidic aryl at the 8-position to specifically modulate the physiol. role of adenosine activation of its various receptors.
IT 98866-49-0
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); BIOL (Biological study)
(xanthine aryl derivative antagonists of adenosine A3 receptor, and therapeutic use)
RN 98866-49-0 CAPLUS
CN Adenosine, N-[(4-amino-3-iodophenyl)methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RE.CNT 65 THERE ARE 65 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L12 ANSWER 47 OF 191 CAPLUS COPYRIGHT 2007 ACS on STN
AN 2001:526078 CAPLUS
DN 135:92808
TI Preparation of methanocarba cycloalkyl nucleoside and nucleotide analogs useful agonists or antagonists of P1 or P2 receptors
IN Jacobson, Kenneth A.; Marquez, Victor E.
PA United States Dept. of Health and Human Services, USA
SO PCT Int. Appl., 74 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2001051490	A1	20010719	WO 2001-US981	20010112
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
	CA 2397366	A1	20010719	CA 2001-2397366	20010112
	AU 2001030913	A5	20010724	AU 2001-30913	20010112
	EP 1252160	A1	20021030	EP 2001-903043	20010112
	EP 1252160	B1	20060816		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
	AT 336492	T	20060915	AT 2001-903043	20010112
	US 2003216412	A1	20031120	US 2002-169975	20020712
	US 7087589	B2	20060808		
	US 2006270629	A1	20061130	US 2006-500860	20060808
PRAI	US 2000-176373P	P	20000114		
	WO 2001-US981	W	20010112		
	US 2002-169975	A3	20020712		

OS MARPAT 135:92808
GI



I



II

AB The present invention provides novel nucleoside and nucleotide derivs. I, wherein R1 is hydrogen, alkyl, cycloalkyl, alkoxy, cycloalkoxy, aryl, arylalkyl, acyl, sulfonyl, arylsulfonyl, thiazolyl or bicyclic alkyl; R2 is hydrogen, halo, alkyl, aryl, arylamino, aryloxide, alkynyl, alkenyl, thiol, cyano, or; R3, R4-R5, are each independently hydrogen, hydroxyl, alkoxy, alkyl, alkenyl, alkynyl, aryl, acyl, alkylamino, arylamino, phosphoryl, diphosphoryl, triphosphoryl, phosphonyl, boronyl, thiophosphoryl, thiodiphosphoryl, thiotriphosphoryl or vanadyl, and can be the same or different; R6 is hydrogen, alkyl, alkenyl, alkynyl, heteroaryl or aminoalkyl; R7 is methylene, dihalomethyl, carbonyl, sulfoxide; and at least one of R1, R2, and R6. is other than hydrogen; R8 is carbon or nitrogen; that are useful agonists or antagonists of P1 or P2 receptors. For example, the present invention provides a compound of formula A-M, wherein A is modified adenine or uracil and M is a constrained cycloalkyl group. The adenine or uracil is bonded to the constrained cycloalkyl group. The compds. of the present invention are useful in the treatment or prevention of various diseases including airway diseases (through A2B, A3, P2Y2 receptors), cancer (through A3, P2 receptors), cardiac arrhythmias (through A1 receptors), cardiac ischemia (through A1, A3 receptors), epilepsy (through A1, P2X receptors), and Huntington's Disease (through A2A receptors). Thus, (N)-Methanocarba-N6-methyl-2-chloro-2'-deoxyadenosine-3,5'-bis(diammonium phosphate) was prepared and tested as agonists or antagonists of P1 or P2 receptor. In binding assays at A1, A2A, and A3 receptors, N-methanocarba-adenosine proved to be of higher affinity than the S-analog, with an N:S-conformation affinity ratio of 150 at the human A3 receptor. Thus, the biol. potency and efficacy of this series of nucleosides appears to be highly dependent on ring puckering, which in turn would influence the orientation of the hydroxyl groups within the receptor binding site. The structure activity relationship (SAR) of adenosine agonists indicates that the ribose ring oxygen may be substituted with carbon. N-Methanocarba N6-(3-iodobenzyl)adenosine and the 2-chloro derivative had Ki values of 4.1 and 2.2 nM at A3 receptors, resp., and were selective partial agonists.

IT 163152-30-5P 163152-31-6P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of methanocarba cycloalkyl nucleoside and nucleotide analogs useful agonists or antagonists of p or p receptors)

RN 163152-30-5 CAPLUS

CN Adenosine, N-[(3-iodophenyl)methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 163152-31-6 CAPLUS
CN Adenosine, 2-chloro-N-[(3-iodophenyl)methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RE.CNT 29 THERE ARE 29 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L12 ANSWER 48 OF 191 CAPLUS COPYRIGHT 2007 ACS on STN
AN 2001:67324 CAPLUS
DN 134:266506
TI New nucleoside analogs, synthesis, and biological properties
AU Wanner, M. J.; Deghati, P. Y. F.; Rodenko, B.; Koomen, G. J.
CS IUPAC Commission, Laboratory of Bioorganic Chemistry, IMC, University of Amsterdam, Amsterdam, 1018 WS, Neth.
SO Pure and Applied Chemistry (2000), 72(9), 1705-1708
CODEN: PACHAS; ISSN: 0033-4545
PB International Union of Pure and Applied Chemistry
DT Journal
LA English
AB A symposium lecture of the authors' work. In view of the importance of nucleoside analogs as enzyme inhibitors and adenosine receptor (ant)agonists, new adenosine analogs were prepared and their activities studied on adenosine deaminase in vitro and on A1, A2A and A3 receptors. Particularly useful for the synthesis of new analogs were the applications of the Pd-catalyzed Buchwald reaction and a radical nitration reaction of purine- and 1-deazapurine nucleosides.
IT 306275-42-3P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
(preparation of nucleoside analogs using Pd-catalyzed Buchwald reaction and a radical nitration reaction of purine- and 1-deazapurine nucleosides)
RN 306275-42-3 CAPLUS
CN Adenosine, N-[(3-iodophenyl)methyl]-2-nitro- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RE.CNT 12 THERE ARE 12 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L12 ANSWER 49 OF 191 CAPLUS COPYRIGHT 2007 ACS on STN
AN 2000:720701 CAPLUS
DN 134:65798
TI Adenosine Analogues as Inhibitors of Trypanosoma brucei Phosphoglycerate Kinase: Elucidation of a Novel Binding Mode for a 2-Amino-N6-Substituted Adenosine
AU Bressi, Jerome C.; Choe, Jungwoo; Hough, Melinda T.; Buckner, Frederick S.; Van Voorhis, Wesley C.; Verlinde, Christophe L. M. J.; Hol, Wim G. J.; Gelb, Michael H.
CS Departments of Chemistry Biochemistry Medicine and Biological Structure, University of Washington, Seattle, WA, 98195, USA
SO Journal of Medicinal Chemistry (2000), 43(22), 4135-4150
CODEN: JMCMAR; ISSN: 0022-2623
PB American Chemical Society
DT Journal
LA English
AB As part of a project aimed at structure-based design of adenosine analogs as drugs against African trypanosomiasis, N6-, 2-amino-N6-, and N2-substituted adenosine analogs were synthesized and tested to establish structure-activity relationships for inhibiting Trypanosoma brucei glycosomal phosphoglycerate kinase (PGK), glyceraldehyde-3-phosphate dehydrogenase (GAPDH), and glycerol-3-phosphate dehydrogenase (GPDH). Evaluation of x-ray structures of parasite PGK, GAPDH, and GPDH complexed with their adenosyl-bearing substrates led the authors to generate a series of adenosine analogs which would target all three enzymes simultaneously. There was a modest preference by PGK for N6-substituted analogs bearing the 2-amino group. The best compound in this series, 2-amino-N6-[2''-(p-hydroxyphenyl)ethyl]adenosine (I), displayed a 23-fold improvement over adenosine with an IC50 of 130 μM. 2-[[2''-(P-Hydroxyphenyl)ethyl]amino]adenosine was a weak inhibitor of T. brucei PGK with an IC50 of 500 μM. To explore the potential of an additive effect that having the N6 and N2 substitutions in one mol. might provide, the best ligands from the two series were incorporated into N6,N2-disubstituted adenosine analogs to yield N6-(2''-phenylethyl)-2-[(2''-phenylethyl)amino]adenosine as a 30 μM inhibitor of T. brucei PGK which is 100-fold more potent than the adenosine template. In contrast, these series gave no compds. that inhibited parasitic GAPDH or GPDH more than 10-20% when tested at 1.0 mM. A 3.0 Å x-ray structure of a T. brucei PGK/I complex revealed a binding mode in which the nucleoside analog was flipped and the ribosyl moiety adopted a syn conformation as compared with the previously determined binding mode of ADP. Mol. docking expts. using QXP and SAS program suites reproduced this "flipped and rotated" binding mode.
IT 23660-96-0P 23660-97-1P 23660-98-2P
23666-24-2P 23707-32-6P 23707-33-7P
26775-34-8P 26775-37-1P 26783-35-7P
26783-37-9P 35940-03-5P 35940-04-6P
313476-98-1P 313476-99-2P 313477-01-9P
313477-04-2P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)

(adenosine analogs as inhibitors of Trypanosoma brucei phosphoglycerate kinase and elucidation of a novel binding mode for a 2-amino-substituted adenosine)

RN 23660-96-0 CAPLUS
CN Adenosine, N-[(4-chlorophenyl)methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 23660-97-1 CAPLUS
CN Adenosine, N-[(3-chlorophenyl)methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 23660-98-2 CAPLUS
CN Adenosine, N-[(2-methoxyphenyl)methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



McIntosh

RN 23666-24-2 CAPLUS
CN Adenosine, N-[(4-methoxyphenyl)methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 23707-32-6 CAPLUS
CN Adenosine, N-[(2-chlorophenyl)methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 23707-33-7 CAPLUS
CN Adenosine, N-[(2-methylphenyl)methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 26775-34-8 CAPLUS

CN Adenosine, 2-amino-N-[(2-methoxyphenyl)methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 26775-37-1 CAPLUS
CN Adenosine, 2-amino-N-[(4-chlorophenyl)methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 26783-35-7 CAPLUS
CN Adenosine, 2-amino-N-[(2-chlorophenyl)methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 26783-37-9 CAPLUS
CN Adenosine, 2-amino-N-[(2-methylphenyl)methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 35940-03-5 CAPLUS
CN Adenosine, N-[(3-methylphenyl)methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 35940-04-6 CAPLUS
CN Adenosine, N-[(4-methylphenyl)methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 313476-98-1 CAPLUS
CN Adenosine, 2-amino-N-[(3-methylphenyl)methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 313476-99-2 CAPLUS
CN Adenosine, 2-amino-N-[(4-methylphenyl)methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 313477-01-9 CAPLUS
CN Adenosine, 2-amino-N-[(3-chlorophenyl)methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 313477-04-2 CAPLUS
CN Adenosine, 2-amino-N-[(4-methoxyphenyl)methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RE.CNT 52 THERE ARE 52 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L12 ANSWER 50 OF 191 CAPLUS COPYRIGHT 2007 ACS on STN
AN 2000:619260 CAPLUS
DN 133:350443
TI 2-Nitro analogues of adenosine and 1-deazaadenosine: synthesis and binding studies at the adenosine A1, A2A and A3 receptor subtypes
AU Wanner, M. J.; Von Frijtag Drabbe Kunzel, J. K.; IJzerman, A. P.; Koomen, G.-J.
CS Institute of Molecular Chemistry, Laboratory of Organic Chemistry, University of Amsterdam, Amsterdam, 1018 WS, Neth.
SO Bioorganic & Medicinal Chemistry Letters (2000), 10(18), 2141-2144
CODEN: BMCLE8; ISSN: 0960-894X
PB Elsevier Science Ltd.
DT Journal
LA English
OS CASREACT 133:350443
AB The influence of nitro substituents on the properties of adenosine and 1-deazaadenosine was studied. Combination of a nitro group at the 2-position with several N6 substituents such as cyclopentyl and m-iodobenzyl gave a series of analogs with good adenosine receptor affinity, showing directable selectivity for the A1, A2A and A3 adenosine receptor subtypes.
IT 306275-42-3P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
(preparation and adenosine receptor binding studies of 2-nitro analogs of adenosine and deazaadenosine)
RN 306275-42-3 CAPLUS
CN Adenosine, N-[(3-iodophenyl)methyl]-2-nitro- (9CI) (CA INDEX NAME)

Absolute stereochemistry.